BioCryst Pharmaceuticals Soars after Positive OpuS-1 Data; Renasas Electronics Plans to Sell Stake in Himax Technologies Unit

Follow this company

Companies Mentioned

05/28/2014 [ACCESSWIRE]

Himax Technologies, Inc. (NASDAQ: HIMX) shares dropped 13.58% after reports revealed that Renasas Eletronics plans to sell its stake in a unit that supplies display driver chips for the Apple iPhone. According to Reuters Renesas will sell its stake to Synaptics. The unit is the sole supplier to for display driver chips in the iPhone.

Himax Technologies, Inc., a fabless semiconductor company, provides display imaging processing technologies to consumer electronics worldwide. The company operates through Driver IC and Non-Driver Products segments. It offers display driver integrated circuits (ICs) and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, and other consumer electronics devices.

Get more information on Himax Technologies, Inc. and free access to the in depth equity report at: wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at to get full access to our free stock reports.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both the primary and secondary endpoints.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop drugs through the structure-guided drug design process.

Get more information on BioCryst Pharmaceuticals, Inc. and free access to the in depth equity report at”


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 


Leave a comment...

Your Name